Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19?

• Main Authors: Aleksandra Hecel (Author), Małgorzata Ostrowska (Author), Kamila Stokowa-Sołtys (Author), Joanna Wątły (Author), Dorota Dudek (Author), Adriana Miller (Author), Sławomir Potocki (Author), Agnieszka Matera-Witkiewicz (Author), Alicia Dominguez-Martin (Author), Henryk Kozłowski (Author), Magdalena Rowińska-Żyrek (Author)
• Format: Book
• Published: MDPI AG, 2020-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Zn(II) is an inhibitor of <i>SARS-CoV-2</i>'s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores-this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.

Item Description

10.3390/ph13090228
1424-8247